Genzyme's diagnostic sales up 10% in 1994
This article was originally published in Clinica
Executive Summary
Genzyme reported a 10% rise in diagnostic product sales to $47 million in 1994, fuelled by a doubling in revenues from sales of the low density lipoprotein (LDL) cholesterol test, which is marketed in the US by SmithKline Beecham. The increase helped Genzyme's total product sales to reach $239 million in 1994, up 30% over the previous year.